Home > Journals > Italian Journal of Dermatology and Venereology > Past Issues > Articles online first > Italian Journal of Dermatology and Venereology 2021 Sep 21

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Italian Journal of Dermatology and Venereology 2021 Sep 21

DOI: 10.23736/S2784-8671.21.07125-5

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Use of apremilast in the psoriasis treatment: a real-life multicentre Italian experience

Federica FILIPPI 1, 2, Annalisa PATRIZI 1, 2 , Luca IEZZI 1, 2, Miriam A. CARPANESE 1, 2, Andrea CONTI 3, Claudia LASAGNI 3, Michela TABANELLI 4, Simone D’ADAMIO 4, Sergio DI NUZZO 5, Chiara CORTELAZZI 5, Vito DI LERNIA 6, Francesca PECCERILLO 6, Monica CORAZZA 7, Giulia ODORICI 7, Federico BARDAZZI 1, 2

1 Dermatology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 2 Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; 3 Dermatology Unit, Surgical, Medical, and Dental Department of Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy; 4 Dermatology Unit, AUSL della Romagna, Ravenna, Italy; 5 Department of Medicine and Surgery, University of Parma, Parma, Italy; 6 Dermatology Unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy; 7 Section of Dermatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy


PDF


BACKGROUND: Apremilast is the first small molecule approved for the treatment of moderate-to-severe psoriasis in adult patients; however, real-life data are still limited. We investigated the effectiveness and safety of this drug in a multicentre real-world setting.
METHODS: We retrospectively reviewed data from all psoriatic patients who received at least one dose of apremilast, collecting demographic data and medical history, at baseline and periodically until 36 months.
RESULTS: A total of 111 patients entered in the study. The mean drug survival duration was 21.8±10.6 months, significantly shorter when comorbidities were≥3 and if biologic drugs were previously administered.ΔPASI90 was achieved in 29% of patients and ΔPASI50 in 68% at T4;the rate of ΔPASI improvement increased progressively at T12, T24, T36 in patients who continued to receive apremilast.At the end of the study 50 patients discontinued the treatment because of adverse events (19.8%), primary failure(19%) or secondary failure(6.3%).
CONCLUSIONS: Apremilast proved to be an effective, safe, and manageable drug, showing effectiveness also in difficult-to-treat patients with psoriasis, with a favourable tolerability profile and a potentially valid weight loss effect. We believe that treating patients with few comorbidities who are naive to biological therapy may result in higher response rates and longer mean drug survival.


KEY WORDS: Psoriasis and apremilast; Psoriasis and small molecules; Psoriasis treatment and real-life; Apremilast effectiveness and safety; Apremilast and drug survival

top of page